Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results by Goyal, K. et al.
Hindawi Publishing Corporation
HPB Surgery
Volume 2010, Article ID 309780, 8 pages
doi:10.1155/2010/309780
Clinical Study
Cyberknife Stereotactic Body Radiation Therapy for
NonresectableTumors of the Liver: PreliminaryResults
K. Goyal,1 D. Einstein,2 M. Yao,2 C.Kunos,2 F. Barton,2 D. Singh,3 C.Siegel,1
J. Stulberg,1 and J. Sanabria1
1Departments of Surgery, University Hospitals-Case Medical Center, Case Western Reserve University,
Cleveland, OH 44106, USA
2Departments of Radiation Oncology, University Hospitals-Case Medical Center, Case Western Reserve University,
Cleveland, OH 44106, USA
3Departments of Medicine, University Hospitals-Case Medical Center, Case Western Reserve University,
Cleveland, OH 44106, USA
Correspondence should be addressed to J. Sanabria, juan.sanabria@uhhospitals.org
Received 24 November 2009; Revised 12 April 2010; Accepted 24 May 2010
Academic Editor: Olivier Farges
Copyright © 2010 K. Goyal et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and
secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of
the liver. Methods. Our ﬁrst 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n = 6), IHC (n = 3), and LM
(n = 8) are presented. Mean radiation dose was 34Gy delivered over 1–3 fractions. Results. Treated patients had a mean decrease
in maximum pretreatment tumor diameter from 6.9±4.6cmto5.0±2.1cm at three months after treatment (P<. 05). The mean
total tumor volume reduction was 44% at six months (P<. 05). 82% of all patients (14/17) achieved local control with a median
follow-up of 8 months. 100% of patients with HCC (n = 6) achieved local control. Patients with surgically placed ﬁducial markers
had no complications related to marker placement. Conclusion. Our preliminary results showed that SBRT is a safe and eﬀective
local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to
deﬁne its role in the management of these malignancies.
1.Introduction
An excess of 80,000 individuals are diagnosed annually
with tumors of the liver in the United States [1]. Less
than 20% of those neoplasms are amenable to deﬁni-
tive surgical management due to advanced stage of local
disease or comorbid medical conditions [2]. Unresectable
malignant tumors of the liver carry a poor prognosis with
limited nonsurgical eﬀective treatment options. Alternative
modalities being used for treatment of unresectable liver
tumors include trans-arterial chemoembolization (TACE),
Y90 microspheres embolization, radiofrequency ablation
(RFA), and transcutaneous ethanol injection (TEI) [3].
However, these therapies have limitations depending on
size, location, number, and distribution of lesions. At this
time, successful systemic therapies for unresectable primary
hepatobiliary malignancies are poorly developed. Sorafenib
is now routinely oﬀered to patients with HCC based on the
randomizedresultsfromtheSHARPtrial[4].Theseformsof
therapy have not had a signiﬁcant impact on survival with a
median overall survival of less than 1 year for nonsurgically
removed primary tumors of the liver [3].
Stereotactic radiosurgery (SRS) is a technique that allows
precisedeliveryofalargeablativeradiationdosetothetumor
while sparing normal surrounding tissue in 1 to 5 fractions.
When used to treat brain metastases, SRS treatment results
in extremely high local control rates in excess of 80%–90%
[5]. Its use in extracranial tumors had been limited due to
the inherent movement of abdominal organs and associated
tumor movement that occurs during the respiratory cycle.
One newer device that tracks tumors during respiration
and automatically adjusts during patient positioning is the2 HPB Surgery
CyberKnife robotic radiosurgery system, which consists of
three key components: (1) an advanced, lightweight linear
accelerator (LINAC), (2) a robotic arm which can point
the LINAC from a wide variety of angles, and (3) a tumor
tracking system. The system tracks a patient’s abdominal
tumor during respiration using three diﬀerent mechanisms:
(1) An in-room kv imaging system, which is used for ﬁducial
tracking, (2) Infrared Light Emitting Diodes (LEDs) placed
on the patient’s chest (synchrony vest) and wall-mounted
infrared detector which allows for the construction of a
patient’s breathing model, and (3) a Software that creates an
algorithm linking the tumor movement with the chest wall
movement, so that tumor position can be predicted at all
stages of the breathing cycle. With the Cyberknife system,
SBRT is delivered in the setting of near real-time tracking
of implanted ﬁducial markers combined with respiratory
motion modeling to achieve submillimeter accuracy by
continually detecting and correcting for tumor motion
throughout treatment. It was reported that the average
treatment delivery precision was 0.3 ± 0.1mmasmeasured
at three diﬀerent SBRT facilities for spinal lesions [6]. SBRT
delivered via the Cyberknife and other radiosurgery systems
has been used in the treatment of several abdominal tumors
including pancreatic, renal, hepatic, adrenal, and pelvic
malignancies among others. We report our initial experience
with 17 patients who underwent SBRT for unresectable
tumors of the liver.
2.MaterialsandMethods
2.1.PatientPopulation. Medicalrecordsoftheﬁrstseventeen
consecutive patients treated between October 2007 and May
2009 who underwent Cyberknife SBRT for nonresectable
tumors of the liver were reviewed under an IRB-approved
protocol. Enrollment criteria for SBRT included (1) biopsy
proven malignancy; (2) nonresectable liver disease, and (3)
life expectancy of at least 12 weeks. Tumor pathology was
represented by HCC (n = 6), IHC (n = 3), and secondary
livertumors(LM,n = 8).PatientstreatedforLMwerefound
to have primary tumors from the GI tract (pancreas and
colorectal, n = 2 and 1, resp.), from the ovary (n = 1), breast
(n = 2), and lung (n = 2).
Four patients underwent surgical resection for abdomi-
nalmalignancypriortoSBRT.ApatientwithIHCunderwent
a nR 0l i v e rr e s e c t i o nt ob ef o u n dt oh a v em u l t i f o c a ld i s e a s e
14 months after initial surgery and 13 months prior to
SBRT. Two patients underwent pancreatico-duodenectomy
for pancreatic adenocarcinoma prior to SBRT for liver
metastases. One patient with liver metastases had sequential
liver resection and RFA 21, 19, and 4 months prior to SBRT.
76% (13/17) of all patients underwent chemotherapy and
52% of them (9/17) underwent locoregional treatments, that
i s ,R F A ,T A C Ep r i o rt oS B R T .
2.2. Stereotactic Body Radiation Therapy (SBRT). Patients
were clinically evaluated by an HPB/transplant surgeon, a
medical oncologist, hepatologist, and a radiation oncologist
and staged by imaging that consisted of contrast-enhanced
computerized tomography (CT scan), magnetic resonance
imaging (MRI), or positron emission tomography scan
(PET). Patients were then discussed at a multidisciplinary
GI tumor board prior to SBRT. Subsequent imaging for con-
touring, treatment plan development, and implementation
was obtained as needed.
An average of 5, 3–5mm cylindrical solid gold ﬁducial
markers (Best Medical International, Springﬁeld, VA) were
placed either surgically (n = 12) or percutaneously under
CT guidance (n = 5) within a 10cm radius within or around
the tumor tissue at a minimum distance between adjacent
ﬁducials of 2cm. Spinal needles and their obturator were
adapted to harbor ﬁducials. In the OR, needles were placed
1-2mm into the liver substance and ﬁducials were pushed in
with the obturator. After needles were removed, hemostasis
was achieved with an Argon photo coagulator. One week was
provided between markers placement and SBRT treatment
planning simulation to allow for ﬁducial settling. Patients
were then brought to the SBRT suite, they were immobilized
using an alpha cradle and ﬁtted with a synchrony vest during
simulationandtreatment.Patientsunderwentimaginginthe
SBRT-immobilized position. These scans were imported into
the Multiplan 2.05 treatment planning system and digitally
fused. Tumor deﬁnition, normal tissue constraints, and ﬁnal
treatment plan were approved by the attending radiation
oncologist, the attending hepatobiliary surgeon, and the
medical physicist. 100 to 300 6MV X-ray beams were used
for each plan. Multiple fraction treatments were performed
on consecutive weekdays. Prior to each treatment fraction,
patients were premedicated with 4mg of dexamethasone
and 4mg of Ondansetron. During SBRT treatment they
were continuously monitored under real-time kilovoltage
cameral ﬁducial tracking and near real-time respiratory
motion modeling using a separate synchrony camera system.
Average treatment time per patient and fraction was 2
hours.
2.2.1. Assessment of Response. Patients were assessed every 3
months after completion of treatment by physical exam and
imaging. CT, MRI, and/or PET scans were performed at each
follow-up. Total volume of the tumor was determined by
Multiplantreatmentplanningsystemv2.05(Sunnyvale,CA).
Themaximumtumordiameterwasmeasuredandthetumor
volume was calculated by importing the image into ADAC
pinnacle radiotherapy planning software with 3D volume
algorithms.
Local response to SBRT was graded by RECIST (Re-
sponse Evaluation Criteria in Solid Tumors) criteria to
describe change in treated tumor lesion [7]. This grading
system has four tumor response grades: Progressive disease
(at least 20% increase of the lesion), stable disease, partial
response (at least 30% decrease of the target lesion), and
complete response (disappearance of all target lesions). To
further evaluate partial tumor response to SBRT and for the
purpose of these studies, we developed a grading system
from I to III and for tumor recurrence from 0 to 4 based on
imaging modalities. Partial response grade I was considered
ad e c r e a s ei nt u m o rv o l u m e / s i z e<30%, but >10% fromHPB Surgery 3
original tumor volume/size. Partial response grade II was
considered as a decrease in volume/size ≥30% but <50%
from original tumor volume/size. Partial response grade III
was considered as a decrease in tumor volume/size ≥50%.
In some instances in patients with IHC, the tumor size was
similar to the original size but the enhancement and PET
activity vanished; we considered these particular cases as a
grade III partial response.
Local or distal recurrent disease was graded as well. Local
recurrence to treatment was deﬁned as tumor progression
within or at the periphery of the radiation ﬁeld. No
recurrence of the tumor was considered grade 0; local
recurrence was considered grade 1 with two subgroups:
grade 1a = 1 local tumor recurrence and grade 1b ≥ 1
local tumor recurrence. Distant intraabdominal recurrence
was considered grade 2 and it was deﬁned as new tumor
distant (>3cms) from the radiation ﬁeld or in another
organ.Furthermore,distantextra-abdominalrecurrencewas
graded as 3. A combination of local and distant recurrence
was considered grade 4.
2.2.2. Adverse Events. Adverse events after SBRT were graded
on a 1–5 scale according to the NCI common terminology
criteria for adverse events v3.0. Causes were attributed to
either surgery, placement of ﬁducial markers, chemotherapy,
radiation induced, or related to medical comorbidities.
2.3. Statistical Assessment. A database of clinical, imaging,
and radiation variables was created and maintained in a
prospective manner. Data were exported to a main frame
computer to be analyzed. Statistical routines were performed
using paired t-test with SPSS V16.0 (Chicago, IL) and
they were considered signiﬁcant at a probability of <.05
level.
3. Results
Seventeen patients were treated with SBRT for nonresectable
tumors of the liver. They consisted of 9 men and 8 women
(n = 17)withameanageof58.1years(range,42to81years).
Treated tumors received a median prescription dose of 34
Grays (24–45Gy) in 1 to 3 (median 3) fractions to a median
prescription isodose line of 70%. Patient demographics and
tumors characteristics are summarized in Table 1. Of the 6
patients treated with SRT for HCC, all of them responded to
treatmentwithadecreaseintumorvolumefrom386±428cc
to 152±78cc (Figure 1). Tumor volume decreased a mean of
60% three months after treatment (P<. 05 by paired t-test).
Similar response rates were observed in patients with liver
metastases. Their tumor volume decreased from 252±292cc
to 103 ± 92cc with a mean tumor shrinkage of 59% at 3
months after SBRT (P<. 05 by paired t-test). It was diﬃcult
to evaluate the response to SBRT in patients with IHC since
these tumors presented in a multicentric fashion with ill-
deﬁned borders. At follow-up, tumors treated were similar
in size but with no enhancement in delay ﬁlms and with
negative PET scans (Figure 2). In the late group of patients,
tumor progression of satellite lesions was the role.
Table 1: Demographics of patients with nonresectable liver tumors
treated with Stereotactic Body Radiation Therapy and baseline
characteristics of the liver malignancies.
HCC IHC LM
S u b j e c t s638
Age (years)
∗62.7
(52–81) 69.3 (61–86) 58.1 (42–77)
Gender(M:F) 4:2 2:1 3:5
Time from Dx
to SBRT
(months)
∗5 (2–11) 8 (3–16) 5.4 (2–11)
Therapy prior
SBRT
S u r g e r y 013
R F A 205
T A C E 200
C h e m o T x 328
Radiation 0 0 0
Tumor
characteristics
Number ∗1 (1) 1 (N/A) 1 (1–6)
Diameter
Max (cm)
∗9.3 (5–22) 4.6 (2–9)
Volume (cc)
∗386
(106–1268) 384 (80–818) 167 (26–433)
Abbreviations: HCC = Hepatocellular carcinoma; IHC = Intrahepatic
cholangiocarcioma; LM = Liver metastases; M:F = Male:Female ratio;
Dx = diagnosis; SBRT = Stereotactic Body Radiation Therapy; RFA
= Radiofrequency ablation; TACE = Trans-arterial chemoembolization.
∗Mean (range).
Initial local control rate to SBRT was 82% (14/17) with
a median follow-up of 8 months (range 3–20 months)
(Table 2). Three patients experienced local recurrence at 1,
4, and 6 months after SBRT. Two recurrences occurred in
patients with secondary tumor of the liver and one in a
patient with IHC. One patient with a liver metastasis from
nonsmall cell lung cancer received a second course of SBRT
(24Gy in 3 fractions) 7 months after initial SBRT for a local
recurrence at the superior edge of the initially treated tumor.
This patient also developed distant bone metastasis and,
thus, was classiﬁed as tumor recurrence grade 4. Another
patient with liver metastasis from pancreatic adenocarci-
noma had local tumor recurrence at 3 months follow-up
imaging. This patient had 2 tumors in two distant locations
withintheliver,whichweretreatedintwoseparateSBRTses-
sions and developed distant intraabdominal metastasis and
was classiﬁed as tumor recurrence grade 4. The third local
failure was a patient with IHC who developed multifocal
local recurrence within edges of radiosurgical ﬁeld 4 months
after SBRT and classiﬁed as tumor recurrence grade 1b.
Seven patients experienced distant recurrences with
mean time to distant progression of 4 months (range 1–7
months) with tumor metastases mainly to the bone (pelvic
bone, clavicle, and/or ribs). Distant recurrence occurred
in 33% (2/6) of patients with HCC at 6 and 7 months,4 HPB Surgery
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Figure 1:Tumor responsein patients withnonresectable liver tumorstreated with Stereotactic Body RadiationTherapy (SBRT).Allpatients
with hepatocellular carcinoma (HCC) responded to SBRT with a mean decrease in tumor volume of 60% at 3 months after therapy (P<. 05
by paired t-test). Similar response was observed in patients with liver metastases (LMs) treated with SBRT with a mean decrease tumor
volume of 59% at 3 months posttreatment (P<. 05 by paired t-test). It was diﬃcult to be certain of the tumor response of patients with
intrahepatic cholangiocarcinoma (IHC) due to the multicentricity of these tumors and the ill-deﬁned edges.
(c) (b) (a)
(f) (e) (d)
Figure 2: Tumor response in a patient with nonresectable and large ICC treated with Stereotactic Body Radiation Therapy (SBRT). (a) CT
scan of the liver showed tumor compromising the liver outﬂow (right, middle, and left hepatic veins) with a satellite lesion in segment 3.
(b)and (C) CT scans of the ICC before and after ﬁducial markers placement. (d) Tumor response by Ct scan and PET scan before (e) and
at 3 months after SBRT (f). Note a “hot” liver mass before SBRT and same liver mass “cold” after treatment. It was found that the precise
deﬁnition of the mass contour was diﬃcult to establish. Although the gross total volume of the mass and its diameter appears to be similar
when sizes were compared before and after treatment, its active tumor load has decreased.HPB Surgery 5
Table 2: Tumor response, recurrence of malignancy, and adverse events in patients treated with Stereotactic Body Radiation Therapy for
nonresectable liver tumors.
HCC IHC LM Total
Subjects 6 3 8 17
Mean of Follow Up (months) 10.0 5.9 6.9 7.8
Tumor Response
RECIST Complete (0) Complete (0) Complete (0) Complete (0)
Partial (5) Partial (2) Partial (7) Partial (4)
Stable (1) Stable (0) Stable (1) Stable (2)
Progress (0) Progress (1) Progress (0) Progress (1)
Partial Tumor Grade I (0) Grade I (2) Grade I (0) Grade I (2)
Response Grade Grade II (3) Grade II (0) Grade II (2) Grade II (5)
Grade III (3) Grade III (1) Grade III (6) Grade III (10)
Tumor Recurrence
Grade 0 (4) Grade 0 (1) Grade 0 (4) Grade 0 (9)
Grade 1a (0) Grade 1a (0) Grade 1a (0) Grade 1a (0)
Grade 1b (0) Grade 1b (1) Grade 1b (0) Grade 1b (1)
Grade 2 (1) Grade 2 (1) Grade 2 (2) Grade 2 (4)
Grade 3 (1) Grade 3 (0) Grade 3 (0) Grade 3 (1)
Grade 4 (0) Grade 4 (0) Grade 4 (2) Grade 4 (2)
Adverse events
From SBRT 0 0 0 0
From markers 0 0 2 2
From surgery 0 0 0 0
# Patients Expired 2 3 3 8
respectively. One of these patients had intraabdominal
distant metastasis, classiﬁed as tumor recurrence grade 2.
The other patient with HCC and distant metastasis had
extra-abdominal metastasis and tumor recurrence grade 3.
One patient with IHC developed bone metastases 4 months
after SBRT, classiﬁed as tumor recurrence grade 2. Distant
recurrence occurred in 50% (4/8) of patients with secondary
tumor of the liver at a mean time of 4 months. Two patients
with pancreatic primary developed distant intraabdominal
metastasis within 3 months of SBRT. The two other distant
recurrences had primary tumors of colorectal and lung
origin. All distant extra-abdominal bone metastases were
treated with conventional radiotherapy.
Regarding treatment-related toxicity, two complications
were observed during percutaneous placement of ﬁducial
markers: one ﬁducial migration and one bleeding compli-
cation requiring angiographic coil (Table 2). Patient admis-
sions to the hospital following SBRT were due to medical
complications and not attributable to SBRT. One patient
with liver metastasis from ovarian primary developed a
ﬂuid collection after receiving an intraabdominal cycle of
chemotherapy which was drained by interventional radiol-
ogy. One patient was admitted for bleeding duodenal ulcer.
This patient had two courses of SBRT from recurrent liver
metastasis from lung primary. He responded to medical
therapy for H. pylori infection. Two other patients had
medical therapy for gastric and duodenal ulcers. One patient
had HCC and the other had liver metastasis from colorectal
primary. Three patients with baseline pain had pain man-
agement procedures performed after SBRT including celiac
plexus block and intrathecal pump. Eight patients expired
at a mean time of six months after SBRT. Each death was
reviewed and considered deﬁnitively not related to SBRT
complications.
4. Discussion
Preliminary analysis of 17 patients treated with SBRT for
unresectable tumors of the liver is presented. All patients
with HCC (n = 6) responded to SBRT as judged by
a 60% decrease in tumor volume. Similar response rates
were observed in patients with liver metastases treated with
SBRT with a mean 59% reduction in their volume after
SBRT. At 3 months follow-up one patient had local tumor
recurrence on imaging after SBRT and two patients had
distant intraabdominal recurrence. At six months follow-
up three patients recurred locally and six patients recurred
distantly. We noted one (6%) grade 3 adverse events due to
ﬁducial placement, two grade 2 GI ulcers, and one grade 3
GI ulcer. On review, radiation doses to duodenal mucosa
were below normal tolerance dose for that organ, but can be
considered as a possible side eﬀect of SBRT.
There are only a few previous studies reporting on the
use of SBRT for primary liver tumors. In 1998 Blomgren et
al. reported no local failures in 11 patients with intrahepatic
primary malignancies. All tumors had either growth arrest,6 HPB Surgery
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Figure 3: Tumor response in a patient with nonresectable and large HCC treated with Stereotactic Body Radiation Therapy (SBRT). (a)
The patient underwent laparoscopy, liver biopsy, intraoperative US and ﬁducial markers placement. (b) The contour of liver tumor was
performed and the development of the SBRT plan was approved. (c) Tumor response at 3 months after surgery. Tumor volume decreased
from 1,293cc to 258cc.
reduction in size, or disappearance of tumor with a mean
survival of 13.4 months after a mean follow-up of 12
months [8]. Romero et al. reported on 11 HCC patients with
a local control rate of 75% after 22 months [9]. Tse et al.
reported a series of 41 patients with HCC (n = 31) or IHC
(n = 10) witha 1 yearlocal controlrate of 65% and a median
survival of 11.7 and 15.0 months, respectively [10]. Two
patients experienced transientbiliary obstruction, whichwas
thought to be due to radiation-induced edema. This was
avoided by the use of pretreatment steroids in subsequent
courses of SBRT. In our study, all six patients with HCC
achieved local control after a median follow-up of 9 months
after SBRT. One patient with IHC failed to respond locally.
Failure to achieve local control in patients with IHC may be
due to the multifocal nature of this tumor’s biology. Taken
together with the current literature, SBRT should be consid-
ered a viable treatment option for patients with unresectable
HCC, unifocal IHC, and metastasis to liver from colorectal,
breast, lung, and ovarian primaries. Based on the signiﬁcant
reduction of HCC tumor volume and size after SBRT in
our study (Figure 3), we have began to use SBRT as another
downstaging modality, in addition to TACE, for tumors over
5cm in maximal diameter in order to make a patient eligible
for liver transplantation according to Milan criteria.
ThemajorityofpreviousreportsusingSBRTtotreatliver
tumors involve the treatment of liver metastases. ReportedHPB Surgery 7
local control rates after SBRT-treated liver metastasis range
from 60%–94% at 2 years [2, 9, 11–17]. Two recent phase
I/II studies reported low incidence of toxicity after SBRT
with a median survival of 20.5 and 17.6 months, respectively
[16, 17]. Both groups noted breast primaries had longer
survival than GI (colorectal, esophageal, HCC) primaries.
75% (6/8) patients treated for liver metastasis in our study
achieved local control. The local failures in our study were
from lung and pancreatic adenocarcinoma primaries. Both
patients who were treated with SBRT for liver metastasis
after pancreaticoduodenectomy and chemoradiation (for
pancreatic adenocarcinoma) developed distant intraabdom-
inal metastasis rapidly within 3 months of SBRT. This
may reﬂect the highly aggressive nature of the pancreatic
primary.
Locoregional therapy with PEI, TACE, or RFA has the
goal of eradicating tumor, while delaying distant progression
bydecreasingtumorburden[18].Ninepatients(33%)inour
studyhadpriortreatmentwithotherlocoregionalmodalities
prior to SBRT: seven patients had RFA for primary or
secondary malignancy of liver and two patients with HCC
had TACE prior to SBRT. All nine patients developed local
tumorprogressionwiththeseothermodalitiespriortoSBRT.
One patient with previous RFA for lung adenocarcinoma
recurred locally and distantly 6 month after SBRT. In a
study by Choi et al., 20 patients were initially treated with
TACE, TEI, or RFA with a local control rate of 80% after
SBRT [19]. This suggests a role for SBRT as salvage therapy
for local recurrence after TACE, TEI, or RFA. Due to
high recurrence rates after TACE and RFA in patients with
primary or secondary liver malignancies, a complementary
local therapy with SBRT in tumors greater than 3cm
may be in order to decrease risk of local recurrence. The
role of SBRT as primary form of therapy deserves further
study.
For patients with HCC, sorafenib, a creatine-kinase
inhibitor is now routinely oﬀered based on results from the
randomized results from the SHARP trial [4]. This study
demonstrated an increase in survival from 10.7 months in
sorafenib group compared to 7.9 months in the placebo
group (P<. 001). Nearly half of the patients with
HCC consented to receive systemic therapy with sorafenib.
We acknowledge that many of these patients with locally
advanced cancer have other medical comorbidities or poor
performance status that may preclude chemotherapy. It is
our practice, all patients with unresectable hepatobiliary
malignancies are oﬀered multimodal treatment including
chemotherapy when medically feasible in addition to the
locally ablative treatment of SBRT. The oncology commu-
nity should be aware that SBRT is a diﬀerent treatment
approach than conventional radiotherapy because the radi-
ation dose in radiosurgery is ablative. Thus, using SBRT
earlier in the natural history of cancer progression (before
second-line chemotherapy) may lead to improved outcomes
[17].
SBRT for unresectable hepatobiliary tumors achieved
excellent local control rates with low adverse events from
radiotherapy or ﬁducial marker placement [2, 8–19]. In
our study multiple approaches were used to place ﬁducial
markers. Of the ﬁve patients with percutaneous ﬁdu-
cial placement, we noted one grade I ﬁducial migra-
tion and one grade III bleeding complication requiring
angiographic coil placement. Twelve patients had ﬁducial
markers placed surgically without any complications. In
our experience, surgical placement of ﬁducial markers is
enhanced by use of the intraoperative ultrasound to detect
tumor(s).
RECIST is most commonly used method to report
response based on measurement of maximal diameter in the
abdominal tumor(s) [7]. However, this grading system is
not the optimal way to assess the entire tumor’s response to
therapy. Measurement of largest two dimensional diameters
is a single snapshot view into tumor eﬀect that can occur
after chemotherapy or locoregional therapy compared to
a three-dimensional assessment of eﬀect based on tumor
volume. Gross tumor volume (GTV) is precisely measured
during treatment planning for SBRT. The same process can
be used after locoregional therapy including SBRT to assess
tumor volume. We report the change in tumor volume
after SBRT based on measuring GTV using the Multiplan
system(Table 2). Amongst the current literature, there are
vague and inconsistent deﬁnitions of tumor response and
recurrence. Without a precise and uniform classiﬁcation
system it is diﬃcult to compare results among studies and
centers. We have developed a grading system for abdominal
tumor response and recurrence using change in tumor
volume after SBRT. We encourage its use in similar cohorts
inanattempttostandardizecomparisonsamongcentersand
among diﬀerent treatment modalities.
It has been suggested that radiographic response analysis
should be set no earlier than 4–6 months after SBRT to
assesstumorresponseinclinicaltrials[18].Futurelong-term
data from randomized clinical trials are needed to determine
the role of SBRT in the treatment of tumors of the liver. It
appearsthatSBRTcanplayaprimaryroleinthelocalcontrol
of these malignancies. The sample size and follow-up of this
study are similar to other reported SBRT studies and add to
the existing literature pertaining to SBRT for hepatobiliary
malignancies. Within the limitations of a small sample size
and short follow-up we have demonstrated that SBRT is a
safe form of therapy for unresectable tumors of the liver with
an 89% local response rate with six months mean follow-
up. Future studies should focus on the development of
strategies to deﬁne the role of SBRT in the treatment of liver
tumors.
5. Conclusions
CyberKnife radiosurgery is a safe and eﬀective local treat-
ment option for unresectable primary and secondary liver
tumors. In the multidisciplinary management of malignant
maladies of the liver, SBRT adds to our armamentarium
of local treatment modalities as complementary or salvage
therapy. The role of SBRT as primary form of therapy
remains to be determined. Further prospective studies are
ongoing to determine long-term response and survival after
SBRT for hepatobiliary malignancies.8 HPB Surgery
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